Murrayanine

Murrayanine

SCHEMBL3087481

COc1cc(C=O)cc2c1[nH]c1ccccc12

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.54
MAPT P10636 6/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
AHR P35869 1/20 0.48
KDM4E B2RXH2 5/20 0.47
ATM Q13315 1/20 0.47
ALDH1A1 P00352 6/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPK1 P28482 2/20 0.44
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537934 0.84 NQO2 (0.54) MAPTMEN1KMT2AKDM4EATM
SCHEMBL19330755 0.83 ALDH1A1 (0.54) MAPTMEN1KMT2AKDM4EALDH1A1
Benzaldehyde SCHEMBL29064698 0.81 MEN1 (0.53) KIF11MAPTMEN1KMT2AKDM4E
SCHEMBL31188786 0.80 KIF11 (0.58) KIF11MAPTMEN1KMT2AAHR
SCHEMBL5992606 0.80 KIF11 (0.58) KIF11MAPTMEN1KMT2AAHR
SCHEMBL11220480 0.78 MAPT (0.60) MAPTMEN1KMT2AKDM4EATM
Murrayafoline A SCHEMBL19127730 0.78 KDM4E (0.55) KIF11MAPTMEN1KMT2AKDM4E
SCHEMBL29655432 0.78 KIF11 (0.56) KIF11MAPTMEN1KMT2AKDM4E
SCHEMBL31188795 0.78 KIF11 (0.56) KIF11MAPTMEN1KMT2AKDM4E
SCHEMBL3244334 0.78 KIF11 (0.55) KIF11MAPTMEN1KMT2AAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113717186-B Preparation method and application of clausena lansium alkaloids 江西农业大学 2022-07-12 CN claimed
CN-113717186-A Preparation method and application of clausena lansium alkaloids 江西农业大学 2021-11-30 CN claimed
CN-109503611-A Mustard seed acid esters (acid, alcohol) and furans [3,2-a] carbazole compound preparation method 云南大学 2019-03-22 CN claimed
US-8519154-B2 Method for treatment of bronchial asthma COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-27 US claimed
CN-101267859-B A pharmaceutical composition useful for the treatment of prostate cancer COUNCIL SCIENT IND RES 2013-01-02 CN claimed
CN-101267859-A A pharmaceutical composition useful for the treatment of prostate cancer COUNCIL SCIENT IND RES (IN) 2008-09-17 CN claimed
CN-122094681-A Carbazole compounds and therapeutic use thereof in the treatment of respiratory infections 2026-05-26 CN disclosed
EP-4743082-A1 CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION UCL Business Ltd (GB) 2026-05-20 EP disclosed
CN-116162054-B Synthesis method of polysubstituted carbazole compound 郑州大学 2025-06-24 CN disclosed
CN-119431217-A Application of carbazole derivative in preventing and controlling plant diseases 广西田园生化股份有限公司 2025-02-14 CN disclosed
US-20250032448-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES KOH, Hwee Ling (SG) 2025-01-30 US disclosed
WO-2025012634-A1 CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION UCL BUSINESS LTD (GB) 2025-01-16 WO disclosed
EP-4099976-B1 MURRAYA KOENIGII EXTRACT AND USE THEREOF IN COSMETICS GATTEFOSSE SAS (FR) 2024-12-04 EP disclosed
EP-1998727-A2 HERBAL COMPOSITION FOR TREATMENT OF INFECTIONS CAUSED BY DERMATOPHYTES Piramal Life Sciences Limited (IN) 2008-12-10 EP disclosed
CN-101267859-A A pharmaceutical composition useful for the treatment of prostate cancer COUNCIL SCIENT IND RES (IN) 2008-09-17 CN disclosed
WO-2007110837-A2 HERBAL COMPOSITION FOR TREATMENT OF INFECTIONS CAUSED BY DERMATOPHYTES PIRAMAL LIFE SCIENCES LIMITED (IN) 2007-10-04 WO disclosed
CN-1893965-A Synergistic composition for treating hyperlipemia COUNCIL SCIENT IND RES (IN) 2007-01-10 CN disclosed
US-6989165-B2 Synergistic composition for treating hyperilipdemia COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-01-24 US disclosed
WO-2005070442-A1 A SYNERGISTIC COMPOSITION FOR TREATING HYPERLIPIDEMIA COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2005-08-04 WO disclosed
US-20050136138-A1 Synergistic composition for treating hyperilipdemia COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032448-A1 COMPOUND FOR USE IN THE TREATMENT AND/OR PREVENTION OF PARASITIC MEDIATED DISEASES EPX, PKD2, MPO KIF11 2575/4885MAPT 1817/4885MEN1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.